Awaiting published exogenous native RCTs · verified registry programs
Watching CB4211 ≠ native · endogenous correlations · compounding rulemaking
Open until “human data” stops meaning three different objects
MOTS-c
Investigation · Thin
When does a strong mitochondrial story
become a therapy you can counsel?
Mitochondrial-derived peptide. Preclinical metabolic intrigue. Exogenous human package thin. Not a recommendation to use, compound, or avoid.
- MoleculeMOTS-c · 16-aa mitochondrial-derived peptide
- ObjectsEndogenous · exogenous native · CB4211 analogue
- Mechanism themeAMPK-related metabolic signaling (preclinical)
- U.S. statusNot FDA approved
- PlacementProvisional → thin investigation (not watchlist)
- Evidence maturityPreclinical substantial · exogenous human thin
Investigation
What is being claimed?
Mitochondrial optimization. Exercise in a vial. Insulin sensitivity and fat loss. Anti-aging staple. “Human data exist.”
People who already know AMPK conversations often assume the mechanism slide is the clinical argument. It isn’t.
Investigation
What is actually known?
Mechanism
Encoded in mitochondrial DNA. Preclinical work links AMPK-related signaling, insulin sensitivity, and exercise-capacity phenotypes in animals. Orientation, not a labeled therapy.
Human evidence split
Endogenous: Observational associations between circulating MOTS-c and metabolic or exercise phenotypes. Biology, not a dosing protocol.
Exogenous native: No published Phase 2/3 RCT package identified for native MOTS-c injections under the usual wellness claims at freeze. FDA staff materials in the 2026 compounding review cycle treated proposed uses as insufficiently supported.
Registry caution: NCT07505745 appears as a Phase 2a native MOTS-c prediabetes trial. Same sponsor cluster previously appeared on a peptide NCT labeled fictional/example. Do not bank it as settled fact without independent verification.
CB4211 analogue: Real Phase 1a/1b program (NCT03998514). Different molecule. Did not become an approved drug. Citing it as “MOTS-c human proof” is an identity error.
Investigation
What remains uncertain?
- Whether native exogenous MOTS-c will show meaningful insulin-sensitivity or body-composition benefits in published RCTs
- How analogue signals would translate to native peptide
- Long-term safety of supraphysiological MDP dosing
- Real RD-ask volume once curiosity noise settles
Still open
- Endogenous level, injectable native, or analogue?
- Is AMPK biology enough for clinic use before exogenous trials?
- Keep on the wall, or demote later?
Investigation
Why should an RD care?
Object literacy. Endogenous MOTS-c, injectable native MOTS-c, and CB4211 are related but not the same. Write the distinction once.
Expectation literacy. AMPK and “exercise mimetic” language describe a biological hypothesis. Clinical counseling still depends on exogenous outcome trials. Training and nutrition still own those outcomes.
Thin-evidence counseling. Curious, precise, unfinished.
Usable line: “MOTS-c is a mitochondrial peptide with interesting animal metabolic data. Most ‘human evidence’ people cite is either blood-level correlations or an analogue called CB4211 that isn’t the same molecule and never became an approved drug. Injectable native MOTS-c doesn’t have a published Phase 2/3 package for the usual insulin-sensitivity claims yet.”
Current thinking
as of July 2026 · subject to revision
MOTS-c is a mitochondrial-derived peptide with a substantial preclinical metabolic story and a thin published package for exogenous native use. Public conversation often borrows credibility from endogenous correlations or from CB4211, a discontinued analogue program. An intelligent stance today is identity-specific and mechanism-curious, careful not to treat AMPK slides or forum protocols as clinical proof. Placement: thin investigation on the wall, not a watchlist one-liner and not an equalized dossier.
Evidence consulted Open file
Evidence consulted while building this notebook. Not a citation for every sentence.
Primary
- CB4211 Phase 1a/1b · CohBar analogue · NCT03998514
- Academic MOTS-c / MDP preclinical literature (AMPK, insulin sensitivity, exercise phenotypes)
- Observational human endogenous MOTS-c correlation studies (as cited in reviews)
Regulatory
- FDA PCAC briefing materials · MOTS-c · Jul 2026 cycle (staff against 503A Bulks List inclusion)
- ClinicalTrials.gov · NCT07505745 (provisional; verify independently)
- WADA / sport-integrity framing for MOTS-c (as reported)
Secondary
- Evidence maps summarizing PCAC peptide briefings (identity / human-gap cross-check)
Placement trail · Jul 2026. News and forums stayed in research notes only.
Frozen thinking artifact v0.1 · Jul 2026 · thin investigation. NCT07505745 not banked as settled. Not medical advice.